Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

Rhea-AI Summary

Evoke Pharma, Inc. (Nasdaq: EVOK) announced a fireside chat scheduled for April 1, 2021, at 1:00 PM ET, hosted by Yale Jen, Senior Biotech Analyst at Laidlaw & Company. The event will feature discussions with Dr. Kostas Sideridis and Dr. Richard McCallum, focusing on GIMOTI, Evoke's nasal spray for treating diabetic gastroparesis. This is a significant advancement as GIMOTI is the first FDA-approved treatment specifically for this GI disorder. Investors can submit questions for the panel prior to the event via email.

Positive

• Evoke's GIMOTI is FDA-approved, offering a unique nasal spray delivery for diabetic gastroparesis treatment.
• The fireside chat provides direct engagement between investors and experts in the field, potentially boosting investor confidence.

Negative

• None.

SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will host a fireside chat on Thursday, April 1, 2021, at 1:00pm ET with Dr. Kostas Sideridis, DO, an early adopter of GIMOTI and co-founder of Long Island Gastro, and Dr. Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso.

Details of the fireside chat are below:
Date:	Thursday, April 1, 2021
Location:	https://edge.media-server.com/mmc/p/hszv2spz
Time:	1:00pm ET

In addition, investors are encouraged to email syndicate@laidlawltd.com prior to the event with questions they may have for Dr. Sideridis and Dr. McCallum. During the call, Laidlaw & Company may be asking several submitted questions to Dr. Sideridis and Dr. McCallum.

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Investor Contacts:
The Ruth Group
Christine Petraglia / James Salierno
Tel: 917-633-8980 / 973-255-8361
cpetraglia@theruthgroup.com / jsalierno@theruthgroup.com

Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com

FAQ

What is Evoke Pharma's planned event on April 1, 2021?

Evoke Pharma is hosting a fireside chat featuring discussions on GIMOTI and diabetic gastroparesis.

Who will be participating in the fireside chat with Evoke Pharma?

The chat will include Dr. Kostas Sideridis and Dr. Richard McCallum.

What is GIMOTI and why is it significant?

GIMOTI is a nasal spray formulation for treating diabetic gastroparesis, the first FDA-approved treatment for this condition.

How can investors participate in the Evoke Pharma fireside chat?

Investors can submit questions via email to Laidlaw & Company prior to the event.

Where can I find more details about the Evoke Pharma event?

Details about the event can be found at the provided link in the press release.